Genetic events in the pathogenesis of multiple myeloma

Jemal, 2007, Cancer statistics, 2007, CA: A Cancer Journal for Clinicians, 57, 43, 10.3322/canjclin.57.1.43 Kyle, 2006, Prevalence of monoclonal gammopathy of undetermined significance, The New England Journal of Medicine, 354, 1362, 10.1056/NEJMoa054494 Landgren, 2006, Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States, Blood, 107, 904, 10.1182/blood-2005-08-3449 Lynch, 2005, Phenotypic heterogeneity in multiple myeloma families, Journal of Clinical Oncology, 23, 685, 10.1200/JCO.2005.10.126 Shapiro-Shelef, 2005, Regulation of plasma-cell development, Nature Reviews. Immunology, 5, 230, 10.1038/nri1572 Kuehl, 2002, Multiple myeloma: evolving genetic events and host interactions, Nature Reviews. Cancer, 2, 175, 10.1038/nrc746 Rajkumar, 1999, Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma, Cancer Genetics and Cytogenetics, 113, 73, 10.1016/S0165-4608(99)00009-6 Salmon, 1973, Immunoglobulin synthesis and tumor kinetics of multiple myeloma, Seminars in Hematology, 10, 135 Katzmann, 2005, Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice, Clinical Chemistry, 51, 878, 10.1373/clinchem.2004.046870 Bradwell, 2003, Serum test for assessment of patients with Bence Jones myeloma, Lancet, 361, 489, 10.1016/S0140-6736(03)12457-9 The International Myeloma Working Group, 2003, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, British Journal of Haematology, 121, 749, 10.1046/j.1365-2141.2003.04355.x Kyle, 2002, A long-term study of prognosis in monoclonal gammopathy of undetermined significance, The New England Journal of Medicine, 346, 564, 10.1056/NEJMoa01133202 Rajkumar, 2005, Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance, Blood, 106, 812, 10.1182/blood-2005-03-1038 Zhan, 2007, Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis, Blood, 109, 1692, 10.1182/blood-2006-07-037077 Kuppers, 2005, Mechanisms of B-cell lymphoma pathogenesis, Nature Reviews. Cancer, 5, 251, 10.1038/nrc1589 Bergsagel, 2001, Chromosome translocations in multiple myeloma, Oncogene, 20, 5611, 10.1038/sj.onc.1204641 Pasqualucci, 2001, Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas, Nature, 412, 341, 10.1038/35085588 Fonseca, 2002, Genomic abnormalities in monoclonal gammopathy of undetermined significance, Blood, 100, 1417, 10.1182/blood.V100.4.1417.h81602001417_1417_1424 Fonseca, 2003, Clinical and biologic implications of recurrent genomic aberrations in myeloma, Blood, 101, 4569, 10.1182/blood-2002-10-3017 Avet-Loiseau, 2001, Blood, 97, 822, 10.1182/blood.V97.3.822 Avet-Loiseau, 2002, Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation, Blood, 99, 2185, 10.1182/blood.V99.6.2185 Hanamura, 2005, Identification of three novel chromosomal translocation partners involving the immunoglobulin loci in newly diagnosed myeloma and human myeloma cell lines, Blood, 106, 10.1182/blood.V106.11.1552.1552 Chesi, 1996, Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines, Blood, 88, 674, 10.1182/blood.V88.2.674.bloodjournal882674 Chesi, 1998, Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma, Blood, 91, 4457, 10.1182/blood.V91.12.4457 Chesi, 1997, Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3, Nature Genetics, 16, 260, 10.1038/ng0797-260 Chesi, 1998, The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts, Blood, 92, 3025, 10.1182/blood.V92.9.3025 Shaughnessy, 2001, Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma, Blood, 98, 217, 10.1182/blood.V98.1.217 Hanamura, 2001, Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations, Japanese Journal of Cancer Research, 92, 638, 10.1111/j.1349-7006.2001.tb01142.x Chesi, 2001, Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma, Blood, 97, 729, 10.1182/blood.V97.3.729 Hurt, 2004, Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma, Cancer Cell, 5, 191, 10.1016/S1535-6108(04)00019-4 Gabrea, 2006, Distinguishing primary and secondary translocations in multiple myeloma, DNA Repair (Amst), 5, 1225, 10.1016/j.dnarep.2006.05.012 Avet-Loiseau, 1999, 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome, Cancer Research, 59, 4546 Fonseca, 2002, Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients, Blood, 99, 3735, 10.1182/blood.V99.10.3735 Hayman, 2001, Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis, Blood, 98, 2266, 10.1182/blood.V98.7.2266 Bergsagel, 2005, Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma, Blood, 106, 296, 10.1182/blood-2005-01-0034 Suzuki, 2005, ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma, Oncogene, 24, 6936, 10.1038/sj.onc.1208844 Keats, 2003, In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression, Blood, 101, 1520, 10.1182/blood-2002-06-1675 Santra, 2003, A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript, Blood, 101, 2374, 10.1182/blood-2002-09-2801 Keats, 2005, Overexpression of transcripts originating from the MMSET Locus characterizes all t(4;14)(p16;q32) positive multiple myeloma patients, Blood, 105, 4060, 10.1182/blood-2004-09-3704 Avet-Loiseau, 2001, Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors, Blood, 98, 3082, 10.1182/blood.V98.10.3082 Shou, 2000, Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma, Proceedings of the National Academy of Sciences of the United States of America, 97, 228, 10.1073/pnas.97.1.228 Zhan, 2006, The molecular classification of multiple myeloma, Blood, 108, 2020, 10.1182/blood-2005-11-013458 Avet-Loiseau, 2007, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome, Blood, 109, 3489, 10.1182/blood-2006-08-040410 Fonseca, 2004, Genetics and cytogenetics of multiple myeloma: a workshop report, Cancer Research, 64, 1546, 10.1158/0008-5472.CAN-03-2876 Sawyer, 1998, Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping, Blood, 92, 4269, 10.1182/blood.V92.11.4269 Sawyer, 2001, Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma, British Journal of Haematology, 112, 167, 10.1046/j.1365-2141.2001.02546.x Fonseca, 2003, The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma, Blood, 102, 2562, 10.1182/blood-2003-02-0493 Bergsagel, 2005, Molecular pathogenesis and a consequent classification of multiple myeloma, Journal of Clinical Oncology, 23, 6333, 10.1200/JCO.2005.05.021 Smadja, 1998, Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases, Leukemia, 12, 960, 10.1038/sj.leu.2401041 Smadja, 2003, Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases, Genes, Chromosomes & Cancer, 38, 234, 10.1002/gcc.10275 Facon, 2001, Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy, Blood, 97, 1566, 10.1182/blood.V97.6.1566 Fonseca, 2002, Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study, Cancer Research, 62, 715 Zojer, 2000, Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization, Blood, 95, 1925, 10.1182/blood.V95.6.1925 Konigsberg, 2000, Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance, Leukemia, 14, 1975, 10.1038/sj.leu.2401909 Avet-Louseau, 2000, Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13, British Journal of Haematology, 111, 1116, 10.1046/j.1365-2141.2000.02488.x Fonseca, 2001, Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy, Leukemia, 15, 981, 10.1038/sj.leu.2402125 Dewald, 1985, The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis, Blood, 66, 380, 10.1182/blood.V66.2.380.380 Sawyer, 1995, Cytogenetic findings in 200 patients with multiple myeloma, Cancer Genetics and Cytogenetics, 82, 41, 10.1016/0165-4608(94)00284-I Shaughnessy, 2000, High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH, Blood, 96, 1505, 10.1182/blood.V96.4.1505 Fonseca, 2001, The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance, Blood, 98, 1271, 10.1182/blood.V98.4.1271 Baker, 2005, Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation, Cell Cycle, 4, 330, 10.4161/cc.4.2.1485 Chang, 2006, Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation, British Journal of Haematology, 135, 486, 10.1111/j.1365-2141.2006.06325.x Fonseca, 2006, Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma, Leukemia, 20, 2034, 10.1038/sj.leu.2404403 Hanamura, 2006, Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation, Blood, 108, 1724, 10.1182/blood-2006-03-009910 Zhan, 2007, CKS1B, over expressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and independent mechanisms, Blood, 109, 4995, 10.1182/blood-2006-07-038703 Bezieau, 2001, High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis, Human Mutation, 18, 212, 10.1002/humu.1177 Liu, 1996, Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial, Blood, 88, 2699, 10.1182/blood.V88.7.2699.bloodjournal8872699 Rasmussen, 2005, Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors, Blood, 105, 317, 10.1182/blood-2004-03-0833 Fonseca, 2003, Implications of N-ras and K-ras mutations in clinical outcome and the biology of multiple myeloma, Blood, 102, 113 Chng, 2007, Clinical significance of TP53 mutation in myeloma, Leukemia, 21, 582, 10.1038/sj.leu.2404524 Corradini, 1994, Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias, Leukemia, 8, 758 Neri, 1993, p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy, Blood, 81, 128, 10.1182/blood.V81.1.128.128 Preudhomme, 1992, Rare occurrence of P53 gene mutations in multiple myeloma, British Journal Haematology, 81, 440, 10.1111/j.1365-2141.1992.tb08253.x Drach, 1998, Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy, Blood, 92, 802, 10.1182/blood.V92.3.802 Xiong, 2006, TP53 gene expression, correlated with 17p13 deletion, is a significant and independent adverse prognostic factor in multiple myeloma treated with high-dose therapy and auto-transplants, ASH Annual Meeting Abstracts, 108, 3394 Annunziata, 2007, Frequent engagement of the classical and alternate NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma, Cancer Cell, 12, 115, 10.1016/j.ccr.2007.07.004 Keats, 2007, Promiscuous mutations activate the non canonical NF-KappaB pathway in multiple myeloma, Cancer Cell, 12, 131, 10.1016/j.ccr.2007.07.003 Dib, 2007, Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma, Blood, 109, 1337, 10.1182/blood-2006-09-049510 Gonzalez-Paz, 2007, Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications, Blood, 109, 1228, 10.1182/blood-2006-05-024661 Dilworth, 2000, Germline CDKN2A mutation implicated in predisposition to multiple myeloma, Blood, 95, 1869, 10.1182/blood.V95.5.1869.005k09_1869_1871 Dib, 2006, Paradoxical expression of INK4 c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression, Cell Division, 1, 23, 10.1186/1747-1028-1-23 Tian, 2003, The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma, The New England Journal of Medicine, 349, 2483, 10.1056/NEJMoa030847 Carrasco, 2006, High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients, Cancer Cell, 9, 313, 10.1016/j.ccr.2006.03.019 Chng, 2006, Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations, Leukemia, 20, 807, 10.1038/sj.leu.2404172 Stewart, 2005, Prognostic and therapeutic significance of myeloma genetics and gene expression profiling, Journal of Clinical Oncology, 23, 6339, 10.1200/JCO.2005.05.023 Greipp, 2005, International staging system for multiple myeloma, Journal of Clinical Oncology, 23, 3412, 10.1200/JCO.2005.04.242 Chang, 2004, The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant, British Journal of Haematology, 125, 64, 10.1111/j.1365-2141.2004.04867.x Winkler, 2003, t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients, British Journal of Haematology, 120, 170, 10.1046/j.1365-2141.2003.03983_5.x Moreau, 2002, Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy, Blood, 100, 1579, 10.1182/blood-2002-03-0749 Gertz, 2005, Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy, Blood, 106, 2837, 10.1182/blood-2005-04-1411 Jaksic, 2005, Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance, Journal of Clinical Oncology, 23, 7069, 10.1200/JCO.2005.17.129 Chang, 2007, Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma, Leukemia Research, 31, 779, 10.1016/j.leukres.2006.08.002 Mateos, 2006, Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study, Blood, 108, 2165, 10.1182/blood-2006-04-019778 Paterson, 2004, Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma, British Journal of Haematology, 124, 595, 10.1111/j.1365-2141.2004.04814.x Trudel, 2004, Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma, Blood, 103, 3521, 10.1182/blood-2003-10-3650 Trudel, 2005, CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma, Blood, 105, 2941, 10.1182/blood-2004-10-3913 Trudel, 2006, The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells, Blood, 107, 4039, 10.1182/blood-2005-10-4179 Chang, 2005, t(11;14) does not predict long-term survival in myeloma, Leukemia, 19, 1078, 10.1038/sj.leu.2403744 Chng, 2007, Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events, Blood, 109, 3610, 10.1182/blood-2006-09-048769 Gutierrez, 2007, Leukemia, 21, 143, 10.1038/sj.leu.2404413 Chang, 2005, p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation, Blood, 105, 358, 10.1182/blood-2004-04-1363 Calasanz, 1997, Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma, British Journal of Haematology, 98, 418, 10.1046/j.1365-2141.1997.2443061.x Fassas, 2002, Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma, British Journal of Haematology, 118, 1041, 10.1046/j.1365-2141.2002.03757.x Smadja, 2001, Hypodiploidy is a major prognostic factor in multiple myeloma, Blood, 98, 2229, 10.1182/blood.V98.7.2229 Stewart, 2007, A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy, Leukemia, 21, 529, 10.1038/sj.leu.2404516 Chng, 2007, Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling, Cancer Research, 67, 2982, 10.1158/0008-5472.CAN-06-4046 Shaughnessy, 2006, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, 109, 2276, 10.1182/blood-2006-07-038430 Dispenzieri, 2007, Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement, Mayo Clinic Proceedings, 82, 323, 10.4065/82.3.323